Another piece of bipartisan legislation was introduced last week that seeks to promote biosimilars.
Another piece of bipartisan legislation was introduced last week that seeks to promote biosimilars.
Senator Mike Enzi, R-Wyoming, and Senator Maggie Hassan, D-New Hampshire, unveiled legislation to enhance education about biosimilars in an effort to increase competition and lower the cost of biologics.
According to a joint statement, the bill has 3 main parts: requiring HHS to create a central website for educational resources on biosimilars; requiring the HHS secretary to establish a database to help medical professionals easily compare data associated with biologic and biosimilar products; and establishing incentives for medical providers to learn more about biosimilars.
It aims to boost the confidence level of both physicians and patients regarding biosimilars’ safety and effectiveness.
The 2 senators cite the slow uptake of biosimilars in the US market, saying that while just 2% of Americans use biologics, they make up 40% of total spending on prescription drugs.
“We are not benefiting from cheaper prescription drug alternatives like biosimilars as much as we should,” Enzi said. “Biosimilars are one of the ways we can do something about healthcare costs without just shifting them elsewhere in the system or implementing administrative price controls. This legislation would help increase confidence in lower-cost biosimilar products, which could drive down drug costs for Americans.”
“Biosimilars have the potential to reduce how much Granite Staters and Americans are spending on drugs, but there is a lack of awareness about these products,” Hassan added. “This bipartisan legislation would help improve awareness and understanding of biosimilars, which in turn could help increase the use of these products and save money for consumers and the federal government.”
A 2017 study by the RAND Corporation estimated the cost savings potential of biosimilars to be $54 billion over 10 years.
Also last week, the Senate Committee on Health, Education, Labor, and Pensions (HELP) released a bill that includes several components related to biosimilars, including one that would require updates to the FDA’s Purple Book, which provides stakeholders with information on biologics. Another part addresses the abuse of citizen petitions.
In addition, that bipartisan bill, sponsored by chairman Lamar Alexander, R-Tennessee, and ranking member Patty Murray, D-Washington, stipulates that the FDA would be required to establish a website for stakeholder education on biologics, including biosimilars and interchangeable products, and allows for the development and improvement of continuing medical education for providers on these topics.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.